Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs

被引:21
作者
Alcon, V
Baca-Estrada, M
Vega-Lopez, M
Willson, P
Babiuk, LA
Kumar, P
Hecker, R
Foldvari, M
机构
[1] Univ Saskatchewan, Coll Pharm & Nutr, Dept Pharmaceut Pharm, Saskatoon, SK S7N 5C9, Canada
[2] Vaccine & Infect Dis Org, Saskatoon, SK, Canada
[3] PharmaDerm Labs Ltd, Saskatoon, SK, Canada
[4] QIAGEN GmbH, Hilden, Germany
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
mucosal immunity; biphasic lipid delivery systems; CpG ODNs; porcine; Actinobacillus pleuropneumoniae;
D O I
10.1208/aapsj070357
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ineffectiveness of simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies of strategies for appropriate delivery systems and adjuvants. Biphasic lipid vesicles are formulations suitable for the delivery of proteins, peptides, and oligo/polynucleotides. The purpose of these studies was to investigate the ability of biphasic lipid vesicles (as vaccine-targeting adjuvants) containing a bacterial antigen and unmethylated oligonucleotides containing CGdinucleotides CpG motifs (CpG ODNs) to induce systemic and mucosal immune responses in pigs. Results showed that while the protein, either alone or with CpG ODNs, did not induce mucosal immune responses, administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in induction of both systemic and local antibody responses after immunization using a combined mucosal/systemic approach.
引用
收藏
页码:E566 / E571
页数:6
相关论文
共 32 条
[1]   Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix™) [J].
Alcón, VL ;
Foldvari, M ;
Snider, M ;
Willson, P ;
Gomis, S ;
Hecker, R ;
Babiuk, LA ;
Baca-Estrada, ME .
VACCINE, 2003, 21 (17-18) :1811-1814
[2]   Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) [J].
Babiuk, S ;
Baca-Estrada, ME ;
Pontarollo, R ;
Foldvari, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (12) :1609-1614
[3]  
Babiuk Shawn, 2004, Current Drug Delivery, V1, P9, DOI 10.2174/1567201043479993
[4]   Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers [J].
Capozzo, AVE ;
Cuberos, L ;
Levine, MM ;
Pasetti, MF .
INFECTION AND IMMUNITY, 2004, 72 (08) :4637-4646
[5]   Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice [J].
De Oliveira, MC ;
Boutet, V ;
Fattal, E ;
Boquet, D ;
Grognet, JM ;
Couvreur, P ;
Deverre, JR .
LIFE SCIENCES, 2000, 67 (13) :1625-1637
[6]  
Farman Cindy A., 2003, Toxicologic Pathology, V31, P119, DOI 10.1080/01926230309779
[7]  
FOLDVARI M, 1999, Patent No. 5993852
[8]  
Foldvari M., 1998, U.S. Patent, Patent No. [5,853,755, 5853755]
[9]   Mucosal immunogenicity and adjuvanticity of cholera toxin in swine [J].
Foss, DL ;
Murtaugh, MP .
VACCINE, 1999, 17 (7-8) :788-801
[10]   Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract [J].
Gallichan, WS ;
Woolstencroft, RN ;
Guarasci, T ;
McCluskie, MJ ;
Davis, HL ;
Rosenthal, KL .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3451-3457